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ABSTRACT
Despite gratifying cure rates in germ cell tumors, conventional-dose chemotherapy achieves long-term
remissions in less than 50% of patients at high risk. High-dose chemotherapy followed by autologous (auto)
peripheral blood stem cell transplantation (PBSCT) has shown impressive remission rates in high-risk and
relapsed germ cell tumors. We report on 64 consecutive patients with high- (n  39), intermediate- (n  18),
and refractory or relapsed low- (n  7) risk germ cell tumors who underwent auto-PBSCT between January
1993 and February 2003. PBSCTs were performed as a single (n  40) or repeated (n  24) transplantation
using either etoposide, ifosfamide, and carboplatin (n  80) or related protocols (paclitaxel, ifosfamide,
carboplatin, etoposide [n  7]; carboplatin, etoposide, thiotepa [n  4]). With a median follow-up of 6 years,
estimated 2- and 5-year overall survivals were 77.2% (95% confidence interval [CI] 66.7-87.7) and 73.1% (95%
CI 61.7-84.5), respectively. We observed unfavorable results in those patients showing refractoriness to
cisplatin (hazard ratio 20.36; 95% CI 6.64-62.47) or no response to induction chemotherapy (hazard ratio
10.67; 95% CI 1.37-83.37). Auto-PBSCT was well tolerated, showed objective antitumor activity, and achieved
long-term survival in patients at high risk and with relapse. Our data suggest that auto-PBSCT can increase
response rates and may improve the outcome in these patients.
© 2006 American Society for Blood and Marrow Transplantation
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GNTRODUCTION
The introduction of platinum-based combination
hemotherapy in the 1970s has substantially improved
he outcome of patients with germ cell tumors (GCT).
ith advanced or relapsed disease, conventional-dose
hemotherapy (CDCT) can cure 70% to 80% of pa-
ients with disseminated disease [1,2]. However, sub-
roups of patients with GCT have a poor prognosis
ith cure rates less than 50% [3]. A particularly un-
avorable outcome is observed in patients refractory to
latinum [4,5], with short relapse-free interval or me-
iastinal primary site [3,6-8]. Initial studies of high- t
B & M Tose chemotherapy (HDCT) with autologous (auto)
tem cell transplantation (SCT) included heavily pre-
reated relapsed or refractory cases, in which a com-
lete remission (CR) was achieved in 24% and long-
erm remission in 15% to 20% [9]. In addition to its
se in patients with second or subsequent relapse,
DCT has also shown encouraging results with early
ntensiﬁcation. Because prospective randomized trials
re still underway, unequivocal recommendations on
he use of HDCT are not yet available.
The aim of our study on 64 patients with advanced
CT was to: (1) describe the overall outcome andoxicity after auto peripheral blood stem cell (PBSC)
355
t
p
o
M
P
i
a
c
t
a
o
a
o
c
n
g
C
ﬁ
r
u
d
p
H
l
b
p
o
a
c
s
a
C
d
s
g
c
f
s
t
t
p
t
p
p
T
w
n
9
m
o
a
e
m
m
c
f
c
n
P
l
I
t
T
A
H
P
E
B
L
I
T
S
A
A. M. S. Müller et al.
3ransplantation (PBSCT); (2) explore clinical factors
rognostic for response and survival; and (3) compare
ur results with those from previous trials.
ETHODS
atients and Eligibility
Sixty-four consecutive patients with GCT, receiv-
ng HDCT with auto-PBSCT between January 1993
nd February 2003, were analysed using medical
harts and electronic records. Follow-up (FU) relating
o survival information was obtained from the tumor
nd PBSCT database. All patients fulﬁlled the criteria
f high- or intermediate-risk disease at diagnosis, in-
ppropriate or delayed response after ﬁrst treatment,
r relapsed disease. Diagnosis of GCT was histologi-
ally proven in all cases and included seminoma and
onseminoma (NS) of gonadal and extragonadal ori-
in. With the development of the International Germ
ell Cancer Collaborative Group (IGCCCG) classi-
cation in 1997, patients treated before this date were
eclassiﬁed and it is this classiﬁcation that has been
sed prospectively ever since [3]. Bulky disease was
eﬁned as tumor mass greater than 5 cm. For each
atient, the following data were obtained: (1) pre-
DCT: age, histology, primary site, disease stage,
ocation of metastases, tumor markers, type and num-
er of cisplatin-based chemotherapy regimens, and
latinum-refractoriness; (2) HDCT: regimen, number
f cycles, response, engraftment, and complications;
nd (3) post-HDCT: type of treatment, progression,
ause of death, event-free survival (EFS) and overall
urvival (OS). HDCTwas performed in patients at high
nd intermediate risk or with inappropriate response to
DCT as primary PBSCT (n  31), or with relapsed
isease as a subsequent salvage attempt (n  33). The
tudy and analysis were carried out according to the
uidelines of the Declaration of Helsinki and good
linical practice. All patients gave their written in-
ormed consent for institutional-initiated research
tudies and speciﬁcally for retrospective analyses of
ransplantation outcomes conforming to our institu-
ional review board guidelines. For this analysis, living
atients were censored as of May 15, 2003, which was
he speciﬁed date (with deﬁnite contact to the patient,
hysician, or relative) for the statistical analysis of our
atient cohort.
reatment Schedule and PBSCT
Median number of CDCT cycles before ﬁrst PBSCT
as 4.5 (range: 1-15). All patients had received plati-
um-based chemotherapy. High-dose regimens (n 
1) were etoposide (1500 mg/m2), ifosfamide (12,000
g/m2), and carboplatin (1500 mg/m2) (n  80) or
ther combinations (paclitaxel [175 mg/m2], ifosf-
mide I [9000 mg/m2], carboplatin [1200 mg/m2], and
56toposide [900 mg/m2] [n  7] or carboplatin [1500
g/m2], etoposide [2400 mg/m2], and thiotepa [450
g/m2] [n  4]). After PBSC collection, cells were
ryopreserved unmanipulated in all patients and rein-
used on day (d) 0. Recombinant human granulocyte
olony-stimulating factor was administered for rapid
eutrophil recovery, starting on day 7 (d7) post-
BSCT and continued until achievement of an abso-
ute white blood cell count of greater than 1  109/L.
n patients with residual tumor mass after HDCT, if
echnically feasible, complete surgical resection was
able 1. Patient Characteristics (n  64)
n %
ge at PBSCT (y; range) 32 (18-54)
istology (n; %)
Seminoma 5 8
Nonseminomatous GCT 59 92
Mixed 38 59
Embryonic 10 16
Teratoma 7 11
Yolk sac 2 3
Chorionic 1 1.5
Anaplastic Ca 1 1.5
rimary tumor location
Testis 52 81
Mediastinum 10 16
Retroperitoneum 2 3
xtranodal metastasis 45 70
Lung only 21 33
Extrapulmonary viscerally 24 37
Lung 42 66
Liver 13 20
Bone 9 14
CNS 8 12
Kidney 2 3
Pancreas 1 2
ulky disease 48 75
ugano stage at PBSCT
IIB 3 5
IIC 10 15
IID 2 3
IIIA 5 8
IIIB 21 33
IIIC 23 36
GCCCG risk
Low 7 11
Intermediate 18 28
High 39 61
ime of PBSCT
Upfront 31 48
First relapse 23 36
>Second relapse 10 16
erum tumor markers n-fold range
-HCG 682 3-115,904
>5,000 mIU/mL 19
>50,000 mIU/mL 10
AFP 103 1-7346
>1,000 ng/mL 21
>10,000 ng/mL 9
LDH 2 1-29
FP indicates alpha fetal protein; -HCG, human chorionic go-
nadotropin; GCT, germ cell tumor; IGCCCG, International
Germ Cell Cancer Collaborative Group; LDH, lactate dehy-
drogenase; PBSCT, peripheral blood stem cell transplantation.
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Chemotherapy with Auto-PBSCT for Germ Cell Tumor
Bttempted. Radiotherapy was considered for sites of
esidual disease, where surgical excision was not pos-
ible, and when tumor markers had failed to normalize
t the end of chemotherapy.
esponse Criteria
Toxicity and response were deﬁned according to
orld Health Organization criteria [10]. Sensitivity
o platinum was classiﬁed according to the response
fter the last cisplatin-based chemotherapy before
DCT. The disease was considered cisplatin-refrac-
ory with evidence of tumor progression within 4
eeks of the last cisplatin-based chemotherapy.
tatistical Analysis
Descriptive data analysis was performed using
he median and the range except where otherwise
tated. EFS was deﬁned as the time from the date of
BSC infusion until the date of treatment failure as
eﬁned by progressive disease (PD), relapse, or
eath from any cause. For censored observations,
urvival state as reported on May 15, 2003, was
sed. Estimates of EFS and OS were obtained using
he Kaplan-Meier method. Univariate analyses were
erformed for the prognostic factors. Univariate
ox proportional hazard regression models were
pplied where possible to obtain hazard ratio (HR)
ith a 95% conﬁdence interval (CI). The corre-
ponding test procedure used was the Wald’s test.
n situations where strata with no events occurred
he log rank test was applied. Associations between
able 2. Clinical Response in Patients with Germ Cell Tumor: Summa
R
Before PBSCT
Immediately after
PBSCT (1 mo) (w
ummarized analysis
CR: 4 (3/1) CR: 38 (20/18)
PR: 47 (26/21) PR: 17 (9/8)
SD: 8 (1/7) SD: 7 (1/6)
PD: 5 (1/4) PD: 2 (1/1)
etailed analysis
CR: 4 CR: 4
PR: 47 CR: 31
PR: 15
SD: 1
SD: 8 CR: 3
PR: 1
SD: 4
PD: 5 PR: 1
SD: 2
PD: 2
n parentheses number of patients receiving PBSCT as upfront ver
Alive.
Deceased.B & M Tifferent prognostic factors were investigated by use
f frequency tables. Multivariate analyses were per-
ormed using the Cox proportional hazard model.
ecause of the small number of events, a parsimo-
ious model was considered. Only some variables
elected to their signiﬁcance in the univariate anal-
sis and their relevance were chosen as candidate
rognostic factors in the multivariate model. Statis-
ical analysis system software (Version 8.2, SAS In-
titute Inc, Cary, NC) was used. Data was analyzed
s of May 15, 2003.
ESULTS
atient Characteristics
As summarized in Table 1, most patients (92%)
ad NS GCT. Primary tumor locations were the testis
n 81%, the mediastinum in 16%, and the retroperi-
oneum in 3%. Extranodal metastases were present in
0% of patients. Median -human chorionic gonad-
tropin (-HCG), alpha fetal protein (AFP), and lac-
ate dehydrogenase (LDH) level increases leading to
BSCT (as calculated from the upper normal value)
ere 682-, 103-, and 2-fold, respectively. Twelve cases
ere deﬁned as cisplatin refractory. Bulky disease was
bserved in 75% of patients. According to IGCCCG,
9% were at high or intermediate risk, and 11% at low
isk, the latter receiving HDCT because of relapsed
isease.
nd Detailed Analyses
e
Best after PBSCT
ltimodal post-PBSCT Treatment) Current
CR: 50 (25/25) CR: 47* (24/23)
PR: 6 (4/2) PR: 1† (1/0)
SD: 6 (1/5) SD: 0
PD: 2 (1/1) PD: 1*/15† (6/10)
CR: 4 CR: 3
PD: 1
CR: 41 CR: 39
PR: 5 PR: 1
SD: 1 PD: 7
CR: 5 CR: 5
SD: 3 PD: 3
PR: 1 PD: 5
SD: 2
PD: 2
vage treatment.rized a
espons
ith Mu
sus sal
BSCT, peripheral blood stem cell transplantation; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.357
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3pheresis Results and Posttransplantation Course
Amedian of one apheresis (range: 1-7) was sufﬁcient
o harvest median CD34 cell numbers of 6  106/kg
ody weight (range: 1.1-34). With infusion of a median
f 3.9  106/kg CD34 cells (range: 1.1-16.9) hemato-
oietic engraftment with white blood cell count greater
han 1  109/L and platelets greater than 20  109/L
ere observed on d10 (range: 7-17) and d11 (range:
-27) after PBSC infusion (d 0), respectively. Infections,
ostly fever of unknown origin, were documented in 48
atients (75%). These were successfully treated in all,
ut one patient developed septic pneumonia and adult
espiratory distress syndrome during neutropenia and
ied on d 6 post-PBSCT, leading to a treatment-
elated mortality (TRM) of 1.6%. Another patient de-
eloped a self-limiting transient tachyarrhythmia and
ne patient with cerebral metastases had a grand mal
eizure after PBSCT. In all others, the HDCT was well
olerated, resulting in a median hospital discharge on
14 (range: 9-47).
reatment Response and Current Remission
After CDCT and before PBSCT, achievement of
R or partial remission (PR) was observed in 80%
f patients. Table 2 depicts responses immediately be-
able 3. Univariate Analysis of Prognostic Factors on Overall Survival
Variables n 1-y O
isplatin Sensitive 52 94.1%
Refractory 12 33.3%
emission at PBSCT CR 11
PR 35
SD/PD 18
-HCG, mIU/mL <50,000 54
>50,000 10
FP, ng/mL <10,000 55
>10,000 9
eminoma Yes 5 100%
No 59 80.8%
GCCCG risk at Dx Low 7
Intermediate 18
High 39
isceral metastases Non 19 94.7%
Pulmonary 21 79.4%
Extrapulmonary 24 74.5%
rimary tumor location Testis  retroperoneal 54 84.8%
Mediastinal 10 68.6%
o. PBSCTs 1 40 89.9%
>1 24 69.1%
ime of PBSCT Upfront 31 83.2%
Relapse 33 81.7%
ge <30 y 26
>30 y 38
ulk No 16
Yes 48
FP indicates alpha fetal protein; -HCG, human chorionic gona
diagnosis; HR, hazard ratio; IGCCCG, International Germ Ce
OS, overall survival; PBSCT, peripheral blood stem cell transplaore and after PBSCT and current remissions status. t
58leven patients required post-PBSCT therapy to
chieve a CR. This treatment consisted of radiation (n
), operation (n 4), chemotherapy plus operation (n
), or chemotherapy alone (n  1). Six patients each
chieved a PR and stable disease (SD) as best response
fter PBSCT. Two patients showed PD despite PBSCT
nd interdisciplinary treatment modalities. None of
hese 14 patients achieved long-term remission (Table
). Five patients, initially in CR after PBSCT, showed
ecurrent disease: one patient with high-risk disease re-
apsed 15 months after the ﬁrst PBSCT. A second PB-
CT was performed, again leading to CR; however,
elapse occurred 4 months later. This patient is currently
rogressive and receiving further CDCT. Two patients
ith recurrent GCT who relapsed 11 and 30 months
fter the ﬁrst PBSCT underwent a second PBSCT and
re in ongoing CR at 5.6 and 7.5 years, respectively.
wo other patients, who received a transplantation for
isease recurrence, relapsed 12 and 8 months after
BSCT. Both died of PD. The current remission status
s an ongoing CR in 47 patients (73%) (Table 2).
ubgroup Analysis
Seminoma versus NS GCT. Patients with seminoma
ere all disease free (four after one PBSCT, one after
CI) 5-y OS (95% CI)
Estimated HR
(95% CI) P value
00) 89.0% (79.8-98.2) 1.00
.0) 8.3% (0-24.0) 20.36 (6.64-62.47) <.0001
1.00
1.19 (0.13; 10.67) .0003
10.67 (1.37; 83.37)
1.00 .028
1.82 (1.07; 3.10)
n.e. .16 (logrank)
100% (–)
1.0) 70.7% (58.5-82.9) n.e. .2 (logrank)
n.e. .29 (logrank)
00) 88.0% (72.2-100) 1.00
7.4) 74.1% (54.5-93.7) 2.65 (0.51; 13.67)
2.2) 58.7% (37.5-79.9) 4.54 (0.98; 21.06) .14
4.5) 76.1% (64.3-88.0) 1.00
8.3) 57.1 (25.0-89.2) 2.20 (0.71; 6.85) .17
9.3) 78.5% (65.1-91.8) 1.00
8.2) 64.5% (44.6-84.4) 1.93 (0.72; 5.17) .19
6.6) 79.0% (63.9-94.1) 1.00
4.9) 67.6% (50.9-84.4) 1.62 (0.59; 4.47) .35
1.00 .88
0.92 (0.34; 2.49)
1.00 .999
1.001 (0.32; 3.11)
in; CI, conﬁdence interval; CR, complete remission; Dx, primary
er Collaborative Group; n.e., not estimable: strata with no events;
; PD, progressive disease; PR, partial remission; SD, stable disease.S (95%
(87.6-1
(6.7-60
(–)
(70.6-9
(84.7-1
(61.3-9
(56.8-9
(75.1-9
(38.9-9
(80.4-9
(49.9-8
(69.7-9
(68.5-9
dotrop
ll Cancwo PBSCTs) and had an estimated OS of 100%.
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Chemotherapy with Auto-PBSCT for Germ Cell Tumor
Batients with NS GCT (n  59) had an estimated
-year EFS of 74.2% (95% CI 63.0-85.5) and 1-year
S of 80.8% (Table 3), with 42 patients being in
ngoing CR.
Primary versus Secondary (With Relapsed Disease)
BSCT. Because of high- (n  22) or intermediate-
n  9) risk disease, 31 patients (48%) received
DCT as a ﬁrst-line therapy and 33 patients as a
ubsequent salvage treatment. Of those patients un-
ergoing upfront transplantation, 58% (n  18 of 31)
eceived one cycle and 42% (n  13 of 31) two
BSCTs. As salvage treatment, single transplantation
as performed in 67% (n  22 of 33) and repetitive
ransplantations in 33% (n  11 of 33). All patients
ad cisplatin-based CDCT regimen before HDCT to
educe tumor mass and mobilize stem cells. In patients
ith ﬁrst-line as compared with secondary PBSCT,
-HCG and AFP were increased in the former group
y 2- and 16-fold, and high-risk disease was present in
1% (22 of 31) versus 48% (16 of 33), respectively.
ith retransfusion of 4 and 3.8 106/kg CD34 cells
n both groups, white blood cell count and platelet
ngraftment was 1 day earlier in the ﬁrst-line PBSCT
ersus secondary transplantation group (d9 versus
10). In addition, fewer platelet transfusions (3 ver-
us 4) were used and earlier discharge from hospital
d14 versus d15) was possible. Table 2 depicts
isease status before and after PBSCT for the upfront
nd salvage groups. Response with currently ongoing
R in both groups was 77.4% versus 69.7%. The
stimated 1-year EFS was 83.5% (95% CI 70.3-96.7)
nd 1-year OS 83.2% for patients undergoing ﬁrst-line
igure 1. Primary versus secondary (with relapsed disease) PBSCT.
3 patients as ﬁrst- or subsequent salvage treatment. Response wi
stimated 5-year OS 79.0% versus 67.6%, respectively.
B & M TBSCT versus an EFS of 69.4% (95%CI 53.6-85.2) and
S of 81.7% for those who underwent transplantation
ith relapsed disease (Table 3, Figure 1).
Single versus Repetitive PBSCT. Single PBSCT was
erformed in 63% and tandem or repetitive PBSCTs in
4 patients (37%). Response rates (CR/PR) were ob-
ained in 77.5% of patients undergoing single versus
6.7% with repetitive PBSCTs. The estimated 1-year
FS was 82.3% (95% CI 70.3-94.2) versus 66.7% (95%
I 47.8-85.5) and 1-year OS 89.9% versus 69.1%, re-
pectively (Table 3). The second PBSCT was applied in
different clinical settings. First, as an upfront intended
andem transplantation to increase dose intensity in 6 of
4 patients. The median time between both transplan-
ations was 30 days (range: 21-46). Of these patients, all
ut one are currently in CR. Second, with inadequate
esponse (either residual tumor mass or persisting
levation of serum tumor markers) to the ﬁrst HDCT
ycle, 12 of 24 patients received a second PBSCT,
ith a median time interval of 76 days (2.3 months;
ange: 27-239 days) between both transplantations. Of
his group with incomplete response to the ﬁrst cycle,
urrently 67% are in CR. One patient died on d6
fter PBSCT because of sepsis (TRM) and 3 patients
ied of tumor progression despite a second cycle of
DCT. Finally, with relapsed disease (after having
chieved a CR with the ﬁrst cycle of HDCT) a second
BSCT was performed in another 6 of 24 patients.
he median time interval between these transplanta-
ions was 13 months (4-, 5-, 9-, 17-, 34-, and 43-
onth time interval). Four patients, who were at high
e of high-risk disease, 31 patients received HDCT as ﬁrst-line, and
ently ongoing CR in both groups was 77.4% versus 69.7%, andBecaus
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3isk at primary diagnosis, died of PD, but two patients
egained a CR with repetitive PBSCT.
Patients with Visceral Metastases and Primary Medi-
stinal Tumor Location. Forty-ﬁve patients had visceral
etastases, with extrapulmonary visceral metastases in
4 patients (37%). Of those patients, 67% are cur-
ently alive and disease free (Figure 2A). Of note is
hat 3 of 9 patients with central nervous tumors are in
ngoing CR.
Ten patients with primary mediastinal tumors un-
igure 2. A, Visceral (pulmonary and extrapulmonary) versus noda
ary and pulmonary manifestation in 24 and 21 patients, respectively
isceral metastases was 88.0%, 74.1%, and 58.7%, respectively.
ediastinal tumor location. As compared with those with nonmedierwent single (n  4) or tandem (n  6) PBSCTs as R
60pfront or salvage treatments in 5 patients each, re-
pectively. Of 10 patients, 6 are disease free and alive.
f those 4 patients showing SD and PD after the ﬁrst
BSCT, two received a second PBSCT after 1 and 4
onths, respectively, but nevertheless died of PD
Figure 2B). Of those receiving PBSCT as upfront
reatment, one died of PD, whereas 4 of 5 patients are
n CR. Notably, 2 of 5 patients with relapsed medias-
inal GCT are in an ongoing CR after PBSCT.
Patients Not Reaching CR after PBSCT and Cisplatin
tases. Forty-ﬁve patients had visceral metastases, with extrapulmo-
ated 5-year OS for nonpulmonary, pulmonary, and extrapulmonary
iastinal versus nonmediastinal GCT. Ten patients had primary
GCT, 5-year OS was 57.1% versus 76.1%, respectively.l metas
. Estim
B, Medesponse. Of 64 patients, 26 did not reach a CR directly
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Chemotherapy with Auto-PBSCT for Germ Cell Tumor
Bfter PBSCT (PR: n  17; SD: n  7; PD: n  2). In
hose patients, PBSCTs had been performed in 11 as
rimary and in 15 patients as secondary PBSCT.
igh-risk disease was present in 69.2% (18 of 26); 15
ases were classiﬁed as cisplatin sensitive and 11 as
efractory. The former group achieved in 12 of 15
80%) a CR after further treatment, the latter pro-
ressed in 10 of 11 patients (91%). In all, 12, 1, and 13
atients are in CR, PR, and PD, respectively.
A total of 31 patients underwent operation after
BSCT for residual tumor mass. In 6 patients (19%),
iable tumor cells were detected, in 5 (16%) teratoma,
nd in the remaining (n  20; 65%) only necrotic
issue.
Of all cases, 12 were cisplatin refractory. Of those
atients with refractory disease, 9 were at high risk
nd 3 were at intermediate risk. Best response after
BSCT in these patients was a CR in one, a PR in 3,
D in 6, and PD in two patients, leading to an ongo-
ng CR in only one patient, the others dying of PD.
isplatin response had a signiﬁcant effect on survival,
ith estimated 1-year EFS in sensitive versus refrac-
ory cases of 92.1% (95% CI 84.7-99.5) versus 8.3%
95% CI 0-24.0), and 1-year OS of 94.1% versus
3.3% (Table 3, Figure 3), respectively.
urvival, Prognostic Factors, and Long-Term FU
All 64 patients were included in the analysis show-
ng 5-year OS and EFS of 73.1% (95% CI 61.7-
4.5%) and 72.3% (95% CI 60.9-83.6%), respec-
ively. With a median FU of 6 years (range: 0.2-10.6),
igure 3. Cisplatin response. Of all cases, 12 were cisplatin refracto
t IGCCCG high risk and 3 at intermediate risk. Best response aft
wo patients, leading to ongoing CR in only one patient, others
stimated 1- and 5-year OS in sensitive versus refractory patients of 94.1%
B & M T8 patients are alive and 47 are disease-free. FU was
onger for patients with single PBSCT (7.65 years) as
ompared with those undergoing repetitive transplan-
ations (4.7 years). Estimated OS after 1, 2, and 5 years
ere 82.3% (95% CI 72.8-91.8), 77.2% (95% CI
6.7-87.7), and 73.1% (95% CI 61.7-84.5), respec-
ively. Patients with IGCCCG low-, intermediate-, or
igh-risk disease had an estimated 1-year EFS of
00%, 71.4% (95% CI 50.2-92,7), and 74.4% (95%
I 60.7-88.1) and 1-year OS of 100%, 76.7% (95%
I 56.7-96.7), and 81.6% (95% CI 69.3-94.0), respec-
ively. Elevated -HCG of less than 50,000 versus
0,000 mU/mL or more resulted in an estimated
-year OS of 86.7% (95% CI 77.6-95.9) versus 58.3%
95% CI 26.8-89.9), respectively. Patients reaching a
R or PR versus SD/PD before PBSCT had an esti-
ated 1-year OS of 100%, 94.2% (95% CI 86.4-
00.0) versus 47.4% (95% CI 23.4-71.4), respectively.
nivariate analysis of prognostic factors on OS
howed a highly signiﬁcant risk for patients with cis-
latin-refractory disease and those achieving only SD
r PD (Table 3). Other prognostic factors showed
levated HR, but did not reach statistical signiﬁcance.
nivariate analyses of prognostic factors on EFS
howed similar results as those on OS, reaching sta-
istical signiﬁcance for cisplatin refractoriness (P 
0001) and remission at PBSCT (P  .0001). In a
ultivariate regression model for selected prognos-
ic variables, only cisplatin refractoriness reached sta-
istic signiﬁcance with a HR of 22.24 (P .0001; 95%
I 6.2-79.77) as compared with visceral extrapulmo-
52 were cisplatin sensitive. Of those with refractory disease, 9 were
CT in these patients was CR in one, PR in 3, SD in 6, and PD in
f PD. Cisplatin response had signiﬁcant effect on survival, withry and
er PBS
dying oand 89% versus 33.3% and 8.3%, respectively.
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3ary metastases (HR 2.8; P  .21; 95% CI 0.56-
3.96), visceral pulmonary metastases (HR 2.36; P 
33; 95% CI 0.43-13.04), or time of PBSCT (upfront
ersus with relapse) with a HR of 0.72 (P  .56; 95%
I 0.24-2.17).
Table 4 summarizes selected earlier trials on
DCT (1996-2004) performed mostly as salvage
herapy in patients with relapse or refractory GCT
n  9 trials) [11-19], but also as ﬁrst-line treatment (n
3 trials) [20-22]. In these previous studies, a median
umber of 70 patients per study were included and
heir median FU was 3.2 years. Six of these trials
ncluded patients undergoing repetitive PBSCTs. In
omparison with these HDCT trials, our study in-
luded a considerable number of patients and with 6
ears, our FU was above average.
ISCUSSION
Although most patients with metastatic GCT can
e cured, 20% to 30% will require salvage treatment
1,2]. In patients with NS GCT, those showing high
umor markers, extrapulmonary visceral metastases,
ediastinal primary sites, or cisplatin-refractory dis-
able 4. Summary of Selected Series Using Autologous Peripheral Bloo
Indication No. No. HDCT
HDCT
Regimen
el/ref 58 1 CEC
el/ref 25 1  6
2  19
CEI
el/ref 150 1 CEI
el 35 1  10
2  25
HD-CTC
el/ref 65 2 CE
el/ref 80 1 CET
el/ref 74 1 CEI
el/ref 80 1  24
2  56
CE/CEI
el/ref 36 1 Carbo-EC-T
st-line in HR 147 1 HD-VIP
st-line in HR 221 3-4 HD-VIP
st-line in HR 18 1  11
2  7
CE/CEI/CEC
st-line/rel/ref 64 1  40
>2  24
VIC/TICE/CET
arbo-EC-T indicates carboplatin, etoposide, cyclophosphamide
cyclophosphamide; CET, carboplatin, etoposide, thiotepa; DFS
FU, follow-up; GCT, germ cell tumor; No. HDCT, number
HDCT regimen, high-dose chemotherapy regimen for PBSCT
ﬁrst-line treatment in patients with high-risk/poor prognosis (IG
free survival; Rel/ref, relapse or refractory GCT; TICE, paclitaxe
VIC or CEI, carboplatin, etoposide, ifosfamide.ase have an unfavorable outcome when treated with p
62DCT alone [3]. Patients with relapsed metastatic
S GCT can achieve remission in 30% to 60%;
owever, only 20% to 50% are long-term survivors
5,8]. Second- or third-line salvage CDCTs no longer
ead to cure. A particularly unfavorable prognosis is
bserved with relapsed primary mediastinal tumors,
eading to long-term disease-free survival with CDCT
n less than 10% [8]. To improve cure rates, various
ultiagent regimens have been used, but have failed
o perform better than standard dose bleomycin, eto-
oside and cisplatin (BEP) in randomized trials.
oreover, increased doses of cisplatin, vincristine, or
leomycin have resulted in higher toxicity [23-25].
Encouraging preclinical and clinical data for a
ose-response relationship for etoposide and ifosf-
mide were the rationale for HDCT regimen in GCT
9,26,27]. Initial studies included patients with heavily
retreated and mostly cisplatin-refractory disease and
chieved objective responses in 24% to 45%, with
ong-term disease-free survivors (15%-20%) even in
nfavorable subgroups [9,11]. Successive HDCT tri-
ls investigated its role earlier in the treatment course,
howing response rates of 30% to 60% in patients
ith relapsed or refractory GCT [15,28,29]. A matched
Cell Transplantation in Germ Cell Tumor
Response FU (mo) Reference
R 40%
S 31% (2y)
28 (10-65) Motzer, 1996 [11]
FS 52% (3y) 26 (14-36) Broun, 1997 [12]
FS 29%
S 39%
55 (21-88) Rick, 1998 [13]
FS 51.3% (2y)
S 64.9% (2y)
37 (12-56) Rodenhuis, 1999 [14]
FS 57% 39 (16-91) Bathia, 2000 [15]
FS 25% (3y)
S 30% (3y)
36 (22-46) Rick, 2001 [16]
.g. 60 (12-96) Beyer, 2002 [17]
FS 32% (2y)
S 40% (2y)
56 (11-166) Vaena, 2003 [18]
FS 48% (2y) OS
% (2y)
29 (4-89) McNeish, 2004 [19]
FS 75% (2y)
S 82% (2y)
21 (0-70) Bokemeyer, 1999 [20]
FS 68% (5y)
S 71% (5y)
47 (0-118) Schmoll, 2003 [21]
R 67%
FS 67%
111 (20-194) De Giorgi, 2004 [22]
FS 72% (5y) OS
% (5y)
72 (2.4-127) Müller, 2005
taxel; CE, carboplatin, etoposide; CEC, carboplatin, etoposide,
e-free survival; EFS, event-free survival; FFS, failure-free survival;
CT-cycles; HD-CTC, carboplatin, thiotepa, cyclophosphamide;
IP, cisplatin, etoposide, ifosfamide; 1st-line in HR, HDCT within
) or advanced disease (Indiana); n.g., not given; PFS, progression
mide, carboplatin, etoposide; Upfront, PBSCT as ﬁrst line therapy;d Stem
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Chemotherapy with Auto-PBSCT for Germ Cell Tumor
Balvage treatment in patients with NS GCT suggested
beneﬁt with HDCT, with an estimated absolute
mprovement in OS of 9% to 11% at 2 years [17].
ith earlier use of HDCT, response rates have im-
roved with simultaneous decline of treatment-related
eaths. HDCT as ﬁrst-line therapy in high-risk GCT
as achieved OS of 67% to 82% [20,30]. A matched
air analysis on HDCT as ﬁrst-line treatment com-
ared with CDCT with standard-dose bleomycin,
toposide and cisplatin or standard-dose etoposide,
fosfamide and cisplatin (BEP/VIP) alone revealed a
igniﬁcant improvement in OS (82% for HDCT ver-
us 71% with CDCT at 2 years) [20]. TandemHDCT
n poor prognosis and relapsed GCT has suggested a
eneﬁt of repetitive HDCT cycles in selected patients,
emonstrating that 52% can survive progression free
or a median of 26 months [12,31]. However, despite
he frequent use of HDCT in poor prognosis GCT
or more than a decade, comparative data on HDCT
nd CDCT are scarce and prospective analyses on
uto-SCT not yet available.
Our analysis describes the outcome of 64 con-
ecutive patients with GCT after HDCT and auto-
BSCT during a 10-year period. We determined clin-
cal factors predictive for response and compared our
esults with those of previous trials. Patients showed
igh- or intermediate-risk according to IGCCCG cri-
eria, relapsed disease, and unfavorable characteristics,
uch as mediastinal primary tumor location, refracto-
iness to cisplatin, extrapulmonary visceral metastases,
nd bulky disease.
Single PBSCT was performed in 63% and tandem
r repetitive PBSCTs in 24 patients (37%). Trans-
lantation was performed as single or repetitive PB-
CTs with response rates (CR/PR) of 77.5% versus
6.7%, respectively. The second PBSCT was applied:
1) as an actual tandem transplantation for increased
ose intensity (25%); (2) with incomplete response to
he ﬁrst HDCT cycle (50%); or (3) with relapse, but
nitial response to the ﬁrst cycle of HDCT (25%).
hose with dose-dense tandem PBSCT (1) had a
otably better response with 83% responders as com-
ared with those relapsing after the ﬁrst PBSCT (3)
33% response rate). Of those patients undergoing a
econd PBSCT as consolidation for residual tumor
fter the ﬁrst transplantation (2), 67% are currently in
R, which may support the use of repetitive PBSCTs
n this clinical context, but nevertheless needs to be
ully evaluated in prospective trials before deﬁnite
ecommendations can be provided.
We conﬁrmed that HDCT is well tolerated: ad-
erse effects consisted mainly of infections, which
ere well controlled with standard treatment. More-
ver, our overall response was favorable, achieving an
stimated 5-year OS of 73.1%. With a median FU of
years, 48 patients (75%) are alive, 47 of whom are
isease-free. Of note is the difference in FU between o
B & M The patients who underwent single transplantation
FU 7.65 years) versus repetitive transplantations (4.7
ears). This seems to be a result of the fact that 13 of
4 patients (54%) undergoing repetitive transplanta-
ion had received this treatment in 1999 or later,
hereas only 14 of 40 (35%) single transplantations
ere performed in the same time period. Another
ossible reason is that repetitive PBSCTs were per-
ormed for heterogenous reasons, as relapse and pro-
ression after the ﬁrst cycle of HDCT, and/or refrac-
oriness to cisplatin. Therefore, this group included
he majority of patients with most unfavorable prog-
ostic features, which led to a shorter FU because of
eath.
Ten patients with primary mediastinal tumor lo-
ation underwent HDCT as ﬁrst-line (n  5) or sal-
age (n  5) therapy. Of these patients, 60% are alive
nd disease-free. Of note is that IGCCCG subgroup
nalysis did not reveal a statistically signiﬁcant differ-
nce in survival for patients at intermediate versus
igh risk. Therefore, the favorable overall outcome of
ur patient cohort did not seem to be positively biased
y the inclusion of patients with intermediate-risk
CT.
We have also conﬁrmed cisplatin response as the
ost important adverse prognostic variable. OS after
uto-PBSCT was 0.8 years in patients with platinum-
nresponsive versus 5.3 years in platinum-sensitive
isease. This matched the signiﬁcantly better results
n patients achieving a CR or PR versus SD/PD be-
ore PBSCT with an estimated 1-year OS of 100%
nd 81% versus 47%, respectively. Of those receiving
DCT as ﬁrst-line treatment, 80% are alive, and 70%
re disease free. Of those patients undergoing HDCT
ith relapse, 57% are alive and disease free. This is
oncordant with previous observations, again suggest-
ng that earlier PBSCT may improve response rates.
Our analysis may be criticized for the retrospec-
ive character of the study, the heterogeneity in ther-
py regimens, and the PBSCT use as ﬁrst-line and
alvage therapy. Nevertheless, this analysis sought to
nclude all consecutive patients with GCT receiving
uto-PBSCTs at two university centers during a 10-
ear period, providing long-term FU in patients with
ntermediate risk, high risk, and relapse. Compared
ith previous HDCT trials [11-22], our study has
ncluded a considerable number of patients and our
U of 6 years was well above average. Encouraging
esults with auto-PBSCT were also obtained in pa-
ients with unfavorable characteristics, which may in
art be a result of our early use of HDCT, consoli-
ation treatment post-HDCT when necessary, and
ow TRM. Although these and previous results are
ntriguing, prospective randomized studies on HDCT
ith PBSCT are lacking and will only allow a deter-
ination of its signiﬁcance compared with CDCT:
ne ongoing study is an European Organization for
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3esearch and Treatment of Cancer phase III trial,
here standard cisplatin, etoposide, and ifosfamide are
ollowed by sequential high-dose cisplatin, etoposide,
nd ifosfamide with PBSCT versus BEP alone in che-
otherapy-naive men with poor prognosis GCT. An-
ther randomized intergroup trial in poor-risk GCT
ompares 4 cycles of BEP with two cycles of BEP
ollowed by HDCT.
In conclusion, we observed impressive EFS and
S with HDCT and auto-PBSCT in GCT with un-
avorable prognostic factors. Toxicity and TRM of
DCTwere remarkably low. Subgroup analysis showed
hat poor response and cisplatin-refractory disease are
he most adverse prognostic factors. Our results sup-
ort the signiﬁcance and efﬁcacy of auto-PBSCT in
dvanced GCT as ﬁrst-line and subsequent therapy,
chieving remarkable responses and thereby poten-
ially improving cancer prognosis. This needs to be
ully determined in ongoing randomized prospective
rials on HDCT as compared with CDCT. Until
hese trials are completed, detailed analyses such as
urs seem to be of signiﬁcance.
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